Literature DB >> 29052597

SYK expression in monomorphic epitheliotropic intestinal T-cell lymphoma.

Grit Mutzbauer1, Katja Maurus1, Clara Buszello1, Jordan Pischimarov1, Sabine Roth1, Andreas Rosenwald1,2, Andreas Chott3, Eva Geissinger1,2.   

Abstract

Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), formerly known as type II enteropathy associated T-cell lymphoma (type II EATL), is a rare, aggressive primary intestinal T-cell lymphoma with a poor prognosis and an incompletely understood pathogenesis. We collected 40 cases of MEITL and 27 cases of EATL, formerly known as type I EATL, and comparatively investigated the T-cell receptor (TCR) itself and associated signaling molecules using immunohistochemistry, amplicon deep sequencing and bisulfite pyrosequencing. The TCR showed both an αβ-T-cell origin (30%) and a γδ-T-cell derivation (55%) resulting in a predominant positive TCR phenotype in MEITL compared with the mainly silent TCR phenotype in EATL (65%). The immunohistochemical expression of the spleen tyrosine kinase (SYK) turned out to be a distinctive feature of MEITL (95%) compared with EATL (0%). Aberrant SYK overexpression in MEITL is likely caused by hypomethylation of the SYK promoter, while no common mutations in the SYK gene or in its promoter could be detected. Using amplicon deep sequencing, mutations in DNMT3A, IDH2, and TET2 were infrequent events in MEITL and EATL. Immunohistochemical expression of linker for activation of T-cells (LAT) subdivided MEITL into a LAT expressing subset (33%) and a LAT silent subset (67%) with a potentially earlier disease onset in LAT-positive MEITL.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29052597     DOI: 10.1038/modpathol.2017.145

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   8.209


  57 in total

1.  Classification of intestinal T-cell neoplasms and their differential diagnosis.

Authors:  A Chott; M Vesely; I Simonitsch; I Mosberger; H Hanak
Journal:  Am J Clin Pathol       Date:  1999-01       Impact factor: 2.493

Review 2.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

3.  Scaffold Protein SLP-76 Primes PLCγ1 for Activation by ITK-Mediated Phosphorylation.

Authors:  Sujan Devkota; Raji E Joseph; Lie Min; D Bruce Fulton; Amy H Andreotti
Journal:  J Mol Biol       Date:  2015-04-25       Impact factor: 5.469

4.  Defective synthesis or association of T-cell receptor chains underlies loss of surface T-cell receptor-CD3 expression in enteropathy-associated T-cell lymphoma.

Authors:  Jennifer M L Tjon; Wieke H M Verbeek; Yvonne M C Kooy-Winkelaar; Binh H Nguyen; Arno R van der Slik; Allan Thompson; Mirjam H M Heemskerk; Marco W J Schreurs; Liesbeth H A Dekking; Chris J Mulder; Jeroen van Bergen; Frits Koning
Journal:  Blood       Date:  2008-09-24       Impact factor: 22.113

5.  Intestinal γδ T-cell lymphomas are most frequently of type II enteropathy-associated T-cell type.

Authors:  Amanda L Wilson; Steven H Swerdlow; Grzegorz K Przybylski; Urvashi Surti; John K Choi; Elias Campo; Massimo M Trucco; S Branden Van Oss; Raymond E Felgar
Journal:  Hum Pathol       Date:  2013-01-17       Impact factor: 3.466

6.  Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas.

Authors:  A L Feldman; D X Sun; M E Law; A J Novak; A D Attygalle; E C Thorland; S R Fink; J A Vrana; B L Caron; W G Morice; E D Remstein; K L Grogg; P J Kurtin; W R Macon; A Dogan
Journal:  Leukemia       Date:  2008-04-10       Impact factor: 11.528

7.  Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology.

Authors:  A Chott; W Haedicke; I Mosberger; M Födinger; K Winkler; C Mannhalter; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

8.  Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Authors:  A Rosenwald; A A Alizadeh; G Widhopf; R Simon; R E Davis; X Yu; L Yang; O K Pickeral; L Z Rassenti; J Powell; D Botstein; J C Byrd; M R Grever; B D Cheson; N Chiorazzi; W H Wilson; T J Kipps; P O Brown; L M Staudt
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

9.  JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma.

Authors:  M-L Nairismägi; J Tan; J Q Lim; S Nagarajan; C C Y Ng; V Rajasegaran; D Huang; W K Lim; Y Laurensia; G C Wijaya; Z M Li; I Cutcutache; W L Pang; S Thangaraju; J Ha; L P Khoo; S T Chin; S Dey; G Poore; L H C Tan; H K M Koh; K Sabai; H-L Rao; K L Chuah; Y-H Ho; S-B Ng; S-S Chuang; F Zhang; Y-H Liu; T Pongpruttipan; Y H Ko; P-L Cheah; N Karim; W-J Chng; T Tang; M Tao; K Tay; M Farid; R Quek; S G Rozen; P Tan; B T Teh; S T Lim; S-Y Tan; C K Ong
Journal:  Leukemia       Date:  2016-02-08       Impact factor: 11.528

10.  Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas.

Authors:  A Nicolae; L Xi; T H Pham; T-A Pham; W Navarro; H G Meeker; S Pittaluga; E S Jaffe; M Raffeld
Journal:  Leukemia       Date:  2016-06-22       Impact factor: 11.528

View more
  6 in total

Review 1.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

Review 2.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 3.  Cellular Origins and Pathogenesis of Gastrointestinal NK- and T-Cell Lymphoproliferative Disorders.

Authors:  Susan Swee-Shan Hue; Siok-Bian Ng; Shi Wang; Soo-Yong Tan
Journal:  Cancers (Basel)       Date:  2022-05-18       Impact factor: 6.575

Review 4.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

5.  Systematic Analysis of Spleen Tyrosine Kinase Expression and its Clinical Outcomes in Various Cancers.

Authors:  Akram I Alwithenani; Mohammad A Althubiti
Journal:  Saudi J Med Med Sci       Date:  2020-04-17

6.  Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma.

Authors:  Soyeon Choi; Yoo Jin Lee; Yunsuk Choi; Misung Kim; Hyun-Jung Kim; Ji Eun Kim; Sukjoong Oh; Seoung Wan Chae; Hee Jeong Cha; Jae-Cheol Jo
Journal:  J Pathol Transl Med       Date:  2022-09-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.